Healthcare

SUPERNUS PHARMACEUTICALS INC

Ticker: SUPN

Exchange: US

Composite FIGI: BBG000BP0HX7

Total Alternative Signals

1signals tracked

Weighted Sentiment

+0.70weighted index

Avg Materiality Score

4.0/ 5.0 scale

Signal Distribution

1▲|0■|0▼

Alternative Data Signal Feed

Real-Time Ingestion Active

Unlock Alternative Signals Feed

Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for SUPERNUS PHARMACEUTICALS INC. Programmatic API and Webhooks available.

Get Premium API Key How does alternative data signal modeling work?

Patent FilingBullish

Filing Date: 2026-06-16

Signal Event Report - FIGI BBG000BP0HX7

Supernus Pharmaceuticals received an update on its patent litigation against Creekwood Pharmaceuticals concerning its drug Qelbree, alleging infringement of six Orange Book-listed patents. The case has been consolidated for unified pretrial proceedings.

Quantitative Investment Thesis

Successful defense of Qelbree patents against generic challengers like Creekwood Pharmaceuticals is crucial for maintaining market exclusivity, protecting future revenue streams, and strengthening the company's long-term earnings potential.

Materiality & Sentiment Scores

Sentiment: 0.7

Materiality: 4 / 5

Source Document: https://patents.justia.com/assignee/supernus-pharmaceuticals-inc